<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1233">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04681001</url>
  </required_header>
  <id_info>
    <org_study_id>COVID-19/CHC_20_04</org_study_id>
    <nct_id>NCT04681001</nct_id>
  </id_info>
  <brief_title>Prophylactic Treatment With Carragelose Nasal Spary to Prevent SARS-CoV-2, COVID-19, Infections in Health Care Workers</brief_title>
  <official_title>Clinical Trial to Evaluate the Efficacy of an Iota-Carrageenan Nasal Spray to Reduce Symptoms Caused by SARS-CoV-2 and Other Respiratory Viruses in Healthcare Workers Managing COVID-19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marinomed Biotech AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Marinomed Biotech AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized placebo-controlled double blinded clinical trial in&#xD;
      frontline healthcare workers managing COVID-19 patients. Participants will be weekly tested&#xD;
      for SARS-CoV-2 and a panel of respiratory viruses. Treatment will be 3times a day for 84 days&#xD;
      one puff into each nostirl and 3 puffs into mouth. Daily a symptom score will be recorded.&#xD;
      The primary objective of the trial is to demonstrate that prophylactic treatment of health&#xD;
      care workers managing COVID-19 patients with iota-carrageenan reduces symptoms of SARS-CoV-2&#xD;
      infections as well as infections with other respiratory viruses when compared to a&#xD;
      placebo-treated control group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized placebo-controlled double blinded clinical trial in&#xD;
      frontline healthcare workers managing COVID-19 patients.&#xD;
&#xD;
      Screening - first day of treatment:&#xD;
&#xD;
      After signing the informed consent form eligible participants will be included. Immediately&#xD;
      after inclusion and after first nasal swab, participants start with their first treatment.&#xD;
&#xD;
      In order to obtain nasal swabs and to assess adverse events the participants will visit the&#xD;
      sites on a weekly basis over a period of 12 weeks.&#xD;
&#xD;
      3 times a day for 84 days (12 weeks):&#xD;
&#xD;
        -  1 puff of Coldamaris pro. nasal spray into each nostril (1.2 mg/ml; 140 µl per puff) and&#xD;
&#xD;
        -  3 puffs of Coldamaris pro. nasal spray into mouth Weekly sampling for testing of&#xD;
           SARS-CoV-2 and respiratory virus panel (Influenza A, Human Metapneumovirus, Influenza A&#xD;
           - subtype H1 Adenovirus, Influenza A - subtype H3 Parainfluenza 1, Influenza A - subtype&#xD;
           2009 H1N1, Parainfluenza 2, Influenza B Parainfluenza 3, SARS-CoV-2 Parainfluenza 4,&#xD;
           Coronavirus HKU1 Respiratory Syncytial Virus A, Coronavirus N63L, Respiratory Syncytial&#xD;
           Virus B, Coronavirus OC43, Rhinovirus/Enterovirus, Coronavirus 229E, Human Bocavirus) At&#xD;
           begin and end of trial blood samples will be taken for differential blood count and for&#xD;
           serology. The primary end point of the is the presence of COVID-19 symptoms including&#xD;
           symptoms of respiratory viral infection. The primary hypothesis is a reduction of&#xD;
           symptom days caused by SARS-CoV-2 and/or respiratory viral infection in health care&#xD;
           workers treated with Coldamaris pro. nasal spray compared to placebo treated ones&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 20, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized placebo-controlled double blinded</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of COVID-19 symptoms including symptoms of respiratory viral infection documented in a diary</measure>
    <time_frame>84 days</time_frame>
    <description>daily assessment of subjective COVID-19 symptom score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nasal swabs for analysis of viruses by PCR</measure>
    <time_frame>84 days</time_frame>
    <description>weekly assessment of SARS-CoV-2, Influenza A, Human Metapneumovirus, Influenza A - subtype H1, Adenovirus, Influenza A - subtype H3, Parainfluenza 1, Influenza A - subtype 2009 H1N1, Parainfluenza 2, Influenza B, Parainfluenza 3, Parainfluenza 4, Coronavirus HKU1, Respiratory Syncytial Virus A, Coronavirus N63L, Respiratory Syncytial Virus B, Coronavirus OC43, Rhinovirus/Enterovirus, Coronavirus 229E, Human Bocavirus, Chlamydophila pneumoniae, Mycoplasma pneumoniae, Legionella pneumophila</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serology of antibodies against SARS-CoV-2</measure>
    <time_frame>84 days</time_frame>
    <description>beginn and end of trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of viral co-infections dedected by PCR</measure>
    <time_frame>84 days</time_frame>
    <description>weekly nasal swabs for analysis of viruses</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Respiratory Viral Infection</condition>
  <condition>Common Cold</condition>
  <condition>Severe Acute Respiratory Syndrome (SARS) Pneumonia</condition>
  <condition>COVID-19</condition>
  <condition>Corona Virus Disease</condition>
  <arm_group>
    <arm_group_label>Coldamaris pro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One puff per nostril three puffs into mouth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Coldamaris sine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One puff per nostril three puffs into mouth</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>nasal spray</intervention_name>
    <description>application of nasal spray into nostrils and mouth</description>
    <arm_group_label>Coldamaris pro</arm_group_label>
    <arm_group_label>Coldamaris sine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Study participants that have given informed consent before any study related&#xD;
             procedures are performed, and received a copy of signed consent form&#xD;
&#xD;
          -  Healthcare workers (nurses, doctors) employed and working at Gesundheitsverbund&#xD;
&#xD;
          -  Healthcare workers looking after confirmed COVID-19 positive patients in a secondary&#xD;
             care setting such as Accident and Emergency departments, wards, operating theatres,&#xD;
             outpatient departments, High Dependency Unit or Intensive Care Units&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject is related to any study personnel or has any other close ties or conflicts&#xD;
             of interest with the study sponsor.&#xD;
&#xD;
          -  The subject has received any investigational drug or participated in a clinical trial&#xD;
             within 4 weeks of entry to this study&#xD;
&#xD;
          -  Known hypersensitivity or allergy to any component of the test product&#xD;
&#xD;
          -  Severe cardiovascular, endocrinological, neurological, respiratory, gastrointestinal&#xD;
             disease or a history or any current disease that is considered by the investigator as&#xD;
             a reason for exclusion.&#xD;
&#xD;
          -  The subject has a clinically significant disease that could interfere with&#xD;
             participation in the study, with the intervention being studied, or with the&#xD;
             evaluation of symptoms. Specific exclusions include immune deficiency, autoimmune&#xD;
             disease, substantive cardiovascular, endocrinological, neurological, respiratory, or&#xD;
             gastrointestinal disease.&#xD;
&#xD;
          -  Asymptomatic disease such as elevated blood pressure or cholesterol will not be a&#xD;
             reason for exclusion. Those with well-controlled mental illness (e.g. depression,&#xD;
             anxiety) will be eligible. The enrolling physician will be empowered to exclude&#xD;
             potential subjects that s/he deems unreliable.&#xD;
&#xD;
          -  Pregnant women at the time of recruitment will be excluded from the study&#xD;
&#xD;
          -  Current medication other than oral contraception, that is considered by the&#xD;
             investigator as a reason for exclusion e.g. intranasal medication&#xD;
&#xD;
          -  Participation in another antiviral clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Iulia Niculescu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gesundheitsverbund; Klinik Favoriten;4. Medizinische Abteilung mit Infektions-und Tropenmedizin1100 Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eva Prieschl-Grassauer, Dr.</last_name>
    <phone>+43226290300</phone>
    <phone_ext>220</phone_ext>
    <email>eva.prieschl-grassauer@marinomed.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicole Unger-Manhart, Dr.</last_name>
    <phone>+43226290300</phone>
    <phone_ext>138</phone_ext>
    <email>nicole.unger-manhart@marinomed.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gesundheitsverbund, Klinik Favoriten</name>
      <address>
        <city>Vienna</city>
        <zip>1100</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iulia Niculescu, Dr.</last_name>
      <phone>+43160191</phone>
      <phone_ext>72471</phone_ext>
      <email>iulia.niculescu@gesundheitsverbund.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gesundheitsverbund Klinik Floridsdorf</name>
      <address>
        <city>Vienna</city>
        <zip>1210</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aschang Valipour, MD</last_name>
      <phone>+43 127700992208</phone>
      <email>arschang.valipour@gesundheitsverbund.at</email>
    </contact>
    <contact_backup>
      <last_name>Waltraud Huf, MD</last_name>
      <phone>+43 127700992208</phone>
      <email>waltraud.huf@gesundheitsverbund.at</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 21, 2020</study_first_submitted>
  <study_first_submitted_qc>December 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2020</study_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Carragelose</keyword>
  <keyword>Respiratory Virus</keyword>
  <keyword>Iota-Carrageenan</keyword>
  <keyword>Health CareWorker</keyword>
  <keyword>Frontline Worker</keyword>
  <keyword>Nasal Spray</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Common Cold</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

